Accuray reported an 8% year-over-year decline in net revenue to $86.5 million for Q1 FY27, primarily due to geopolitical challenges in China. Despite this, the company achieved a positive adjusted EBITDA of $2.5 million, a significant improvement from a $4.1 million loss in the prior year, driven by a 4% increase in service revenue and a 25% reduction in operating expenses. Product revenue fell 26%, and the book-to-bill ratio of 0.7 indicates ongoing pressure on future hardware sales.
Original sourceARAYNASDAQHealthcare
ACCURAY INC
Public company snapshot, recent ticker-linked headlines, and a path into evidence-backed AI research.
Latest price
$0.11
-11.22%
Alpha Vantage · 11/6/2026
Industry: Medical DevicesCategory: Domestic Common StockCurrency: USDNews: 1 recent
Analyze ARAY free One-year price history
Adjusted daily closes · 252 observations · as of Nov 6, 2026
1 month
-54.4%
3 months
-62.3%
6 months
-71.0%
1 year
-91.0%
Year to date
-86.7%
52-week range
$0.11 – $1.22
Fundamental snapshot
Latest reported period: Jun 30, 2026
Market cap
$13.1M
P/E
-0.3
P/B
0.3
P/S
0
Revenue
$401.95M
Net income
-$49.19M
Diluted EPS
-0.4
Gross margin
27.70%
Net margin
-12.20%
Return on equity
-99.00%
Total debt
$183.87M
Cash
$48.77M
Free cash flow
-$19.26M
Latest eight reported quarters
Reported quarterly values, newest first
| Period | Revenue | Net income | Gross margin | Net margin | Free cash flow |
|---|---|---|---|---|---|
| Jun 30, 2026 | $100.92M | -$1.94M | 34.80% | -1.90% | $1.07M |
| Mar 31, 2026 | $104.85M | -$11.81M | 24.10% | -11.30% | -$7.11M |
| Dec 31, 2025 | $102.24M | -$13.77M | 23.50% | -13.50% | -$21.58M |
| Sep 30, 2025 | $93.94M | -$21.68M | 28.30% | -23.10% | $8.36M |
| Jun 30, 2025 | $127.54M | $1.12M | 30.60% | 0.90% | -$13.11M |
| Mar 31, 2025 | $113.24M | -$1.3M | 27.90% | -1.10% | $15.63M |
| Dec 31, 2024 | $116.17M | $2.54M | 36.10% | 2.20% | $231K |
| Sep 30, 2024 | $101.55M | -$3.95M | 33.90% | -3.90% | -$8.41M |
Reported figures can reflect company reporting conventions, restatements, or sector-specific accounting. Verify against filings before relying on a valuation comparison.
Recent ARAY news
All market newsscanx.trade·60 signal
Accuray Q1FY27 Results: Revenue down 8% YoY as China headwinds persist